Elicio Therapeutics reports inducement grants

Elicio Therapeutics announced that on October 15, 2024, Elicio granted an aggregate of 5,900 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. Each grant provides for the purchase of shares of Elicio common stock at a price of $4.49 per share, the closing price per share of Elicio common stock as reported by Nasdaq on October 15, 2024, the date of grant. The grants vest over four years, with 25 percent of the shares vesting on the first anniversary of each employee’s respective start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.